Uneingeschränkter Zugang

Cytotoxic responses of human chondrocytes to bupivacaine, levobupivacaine, and ropivacaine

Pudkrong Kaewpichit

Pudkrong Kaewpichit

Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial HospitalBangkok, Thailand
Suche nach diesem Autor auf
Sciendo|Google Scholar
Kaewpichit, Pudkrong
, 
Somrat Charuluxananan

Somrat Charuluxananan

Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial HospitalBangkok, Thailand
Suche nach diesem Autor auf
Sciendo|Google Scholar
Charuluxananan, Somrat
, 
Monpichar Srisa-Art

Monpichar Srisa-Art

Department of Chemistry, Faculty of Science, Chulalongkorn UniversityBangkok, Thailand
Suche nach diesem Autor auf
Sciendo|Google Scholar
Srisa-Art, Monpichar
, 
Sarocha Sisawat

Sarocha Sisawat

Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial HospitalBangkok, Thailand
Suche nach diesem Autor auf
Sciendo|Google Scholar
Sisawat, Sarocha
, 
Vitavat Aksornkitti

Vitavat Aksornkitti

Nanomedicine Research Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand
Suche nach diesem Autor auf
Sciendo|Google Scholar
Aksornkitti, Vitavat
, 
Chalermsri Chayudsatid

Chalermsri Chayudsatid

Nanomedicine Research Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand
Suche nach diesem Autor auf
Sciendo|Google Scholar
Chayudsatid, Chalermsri
 und 
Amornpun Sereemaspun

Amornpun Sereemaspun

Nanomedicine Research Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand
Suche nach diesem Autor auf
Sciendo|Google Scholar
Sereemaspun, Amornpun
  
25. Sept. 2019
Cytotoxic responses of human chondrocytes to bupivacaine, levobupivacaine, and ropivacaine's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
COVER HERUNTERLADEN
Artikel-Kategorie: Brief communication (original)
Online veröffentlicht: 25. Sept. 2019
Seitenbereich: 169 - 178
DOI: https://doi.org/10.1515/abm-2019-0017
Schlüsselwörter
© 2018 Pudkrong Kaewpichit et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Figure 1

Effect of local anesthetics on viability of CHON-001 cells after 15-, 30-, 60-, and 120-min exposure as determined by FITC-conjugated annexin V and PI staining and cytometry using a Beckman Coulter Epics XL flow cytometer. The sets of bars represent the mean percentages of chondrocyte viability after treatment with local anesthetic or controls; from left to right, PBS vehicle control (black bars), 0.4 mM H2O2 positive control (dark-gray bars), 0.25% ropivacaine (medium-gray bars), 0.5% ropivacaine (medium-gray bars), 0.25% levobupivacaine (light-gray bars), 0.5% levobupivacaine (light-gray bars), 0.25% bupivacaine (white bars), 0.5% bupivacaine (white bars). Low (0.25%) and high (0.5%) concentrations of bupivacaine and 0.5% levobupivacaine treated groups significantly decreased cell viability at 60 min, compared with treatment by the PBS vehicle control. **P < 0.001, ***P < 0.001; error bars represent standard deviation; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; PI, propidium iodide
Effect of local anesthetics on viability of CHON-001 cells after 15-, 30-, 60-, and 120-min exposure as determined by FITC-conjugated annexin V and PI staining and cytometry using a Beckman Coulter Epics XL flow cytometer. The sets of bars represent the mean percentages of chondrocyte viability after treatment with local anesthetic or controls; from left to right, PBS vehicle control (black bars), 0.4 mM H2O2 positive control (dark-gray bars), 0.25% ropivacaine (medium-gray bars), 0.5% ropivacaine (medium-gray bars), 0.25% levobupivacaine (light-gray bars), 0.5% levobupivacaine (light-gray bars), 0.25% bupivacaine (white bars), 0.5% bupivacaine (white bars). Low (0.25%) and high (0.5%) concentrations of bupivacaine and 0.5% levobupivacaine treated groups significantly decreased cell viability at 60 min, compared with treatment by the PBS vehicle control. **P < 0.001, ***P < 0.001; error bars represent standard deviation; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; PI, propidium iodide

Figure 2A–D

Pattern of CHON-001 cell death after 120 min exposure to local anesthetics as analyzed using a Beckman Coulter Epics XL flow cytometer after staining with annexin V-conjugated FITC and PI. Compared with chondrocytes treated with PBS vehicle as a control (A), the numbers of necrotic chondrocytes increased after treatment with 0.25% bupivacaine (C), 0.5% bupivacaine (D), 0.4 mM H2O2 positive control (B) FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; PI, propidium iodide
Pattern of CHON-001 cell death after 120 min exposure to local anesthetics as analyzed using a Beckman Coulter Epics XL flow cytometer after staining with annexin V-conjugated FITC and PI. Compared with chondrocytes treated with PBS vehicle as a control (A), the numbers of necrotic chondrocytes increased after treatment with 0.25% bupivacaine (C), 0.5% bupivacaine (D), 0.4 mM H2O2 positive control (B) FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; PI, propidium iodide

Figure 2E–H

Pattern of CHON-001 cell death after 120 min exposure to local anesthetics as analyzed using a Beckman Coulter Epics XL flow cytometer after staining with annexin V-conjugated FITC and PI. The numbers of necrotic chondrocytes increased after treatment with 0.25% levobupivacaine (E), 0.5% levobupivacaine (F), while chondrocytes treated with ropivacaine (G, H) showed no substantial difference in cell viability compared with those treated with PBS vehicle as a control (A). FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; PI, propidium iodide
Pattern of CHON-001 cell death after 120 min exposure to local anesthetics as analyzed using a Beckman Coulter Epics XL flow cytometer after staining with annexin V-conjugated FITC and PI. The numbers of necrotic chondrocytes increased after treatment with 0.25% levobupivacaine (E), 0.5% levobupivacaine (F), while chondrocytes treated with ropivacaine (G, H) showed no substantial difference in cell viability compared with those treated with PBS vehicle as a control (A). FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; PI, propidium iodide

Figure 3

Production of dermatan sulfate by bupivacaine-treated CHON-001 cells as determined by a Beckman Coulter P/ACE MDQ capillary electrophoresis system equipped with a photodiode array detector operating at 195 nm (AU). (A) Dermatan sulfate production by chondrocytes treated with 0.125% bupivacaine for 24 h was greater than production by chondrocytes treated with 0.25% bupivacaine for 24 h. Labeled peaks correspond to dermatan sulfate showing migration time (min) and relative area under the peak (arbitrary units). Treatments for 24 h as indicated. (B) Bars show the relative increase in dermatan sulfate production by the chondrocytes after the various treatments including both concentrations of bupivacaine (single measurements). AU, arbitrary units; DMEM, Dulbecco’s modified Eagle’s medium
Production of dermatan sulfate by bupivacaine-treated CHON-001 cells as determined by a Beckman Coulter P/ACE MDQ capillary electrophoresis system equipped with a photodiode array detector operating at 195 nm (AU). (A) Dermatan sulfate production by chondrocytes treated with 0.125% bupivacaine for 24 h was greater than production by chondrocytes treated with 0.25% bupivacaine for 24 h. Labeled peaks correspond to dermatan sulfate showing migration time (min) and relative area under the peak (arbitrary units). Treatments for 24 h as indicated. (B) Bars show the relative increase in dermatan sulfate production by the chondrocytes after the various treatments including both concentrations of bupivacaine (single measurements). AU, arbitrary units; DMEM, Dulbecco’s modified Eagle’s medium

Figure 4

ROS production by CHON-001 cells after exposure to local anesthetics for 0–60 min as determined by 2′,7′-dichlorodihydrofluorescein diacetate reagent. The chondrocytes were treated with PBS vehicle as a control (black bars), bupivacaine (white bars) 0.25% (A) and 0.5% (B), ropivacaine (dark-gray bars) 0.25% (C) and 0.5% (D), levobupivacaine (light-gray bars) 0.25% (E) and 0.5% (F). The local anesthetics immediately decreased ROS production compared with PBS. *P < 0.05, **P < 0.01, and ***P < 0.001; error bars represent standard deviation m, minutes; PBS, phosphate-buffered saline; ROS, reactive oxygen species
ROS production by CHON-001 cells after exposure to local anesthetics for 0–60 min as determined by 2′,7′-dichlorodihydrofluorescein diacetate reagent. The chondrocytes were treated with PBS vehicle as a control (black bars), bupivacaine (white bars) 0.25% (A) and 0.5% (B), ropivacaine (dark-gray bars) 0.25% (C) and 0.5% (D), levobupivacaine (light-gray bars) 0.25% (E) and 0.5% (F). The local anesthetics immediately decreased ROS production compared with PBS. *P < 0.05, **P < 0.01, and ***P < 0.001; error bars represent standard deviation m, minutes; PBS, phosphate-buffered saline; ROS, reactive oxygen species

Figure 5

NO production by CHON-001 cells after exposure to local anesthetics for 120 min as measured by using a colorimetric Nitrite/Nitrate Assay kit. The bars represent the mean NO production after treatment with PBS vehicle as a control (black bars), bupivacaine (white bars, 0.25% left, 0.5% right), levobupivacaine (light-gray bars, 0.25% left, 0.5% right), ropivacaine (medium-gray bars, 0.25% left, 0.5% right), and 0.4 mM H2O2 (dark-gray bars, far right). *P < 0.05, **P < 0.01, and ***P < 0.001; error bars represent standard deviation; m, minutes; NO, nitric oxide
NO production by CHON-001 cells after exposure to local anesthetics for 120 min as measured by using a colorimetric Nitrite/Nitrate Assay kit. The bars represent the mean NO production after treatment with PBS vehicle as a control (black bars), bupivacaine (white bars, 0.25% left, 0.5% right), levobupivacaine (light-gray bars, 0.25% left, 0.5% right), ropivacaine (medium-gray bars, 0.25% left, 0.5% right), and 0.4 mM H2O2 (dark-gray bars, far right). *P < 0.05, **P < 0.01, and ***P < 0.001; error bars represent standard deviation; m, minutes; NO, nitric oxide
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
6 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Medizin, Gesundheitsfachberufe, Vorklinische Medizin, Grundlagenmedizin, Vorklinische Medizin, Grundlagenmedizin, andere, Klinische Medizin, Klinische Medizin, andere
Zeitschrift RSS Feed